Activity during the Lung
Response to Silica Particles in NMRI Mice
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |
Abstract |
|---|
|
|
|---|
We have found reduced activity of tumor necrosis factor (TNF)-
accompanying resolving and fibrosing
alveolitis induced in NMRI mice by mineral particles (MnO2 and SiO2, respectively), which is in apparent
contradiction to the well-recognized proinflammatory and profibrotic activities of this cytokine. The objective of this study was to examine the mechanisms involved in this paradoxical response in NMRI mice.
Although lung tissue messenger RNA (mRNA) levels for TNF-
were transiently (up to 15 d) and persistently (up to 120 d) upregulated in the resolving and fibrosing models, respectively, these changes were not
accompanied by a parallel release of TNF-
protein, which was respectively transiently and persistently
downregulated in bronchoalveolar lavage fluid and bronchoalveolar lavage cell cultures. The downregulation of the TNF-
protein was concurrent with the accumulation of recruited polymorphonuclear neutrophils (PMNs) in alveoli, and coculture experiments showed that PMN explanted from the lungs of mice
treated with silica particles were able to downregulate the expression of TNF-
protein by naive alveolar
macrophages. In addition, PMN depletion prevented the downregulation of TNF-
induced by silica, further establishing the role of PMNs in the downregulation of TNF-
. The possible degradation of TNF-
by proteolytic enzymes could be excluded. Marked increases in soluble p55 and p75 TNF receptors
(sTNF-R), as well as in interleukin (IL)-10, paralleled the downregulation of TNF-
protein. The role of
these mediators in the observed reduction of TNF-
activity was confirmed by immunoneutralizing the activity of p55 and p75 sTNF-R and by using IL-10-deficient animals. Because IL-10 also exerts profibrotic
activity in addition to its antiinflammatory activity, the protracted overproduction of IL-10 observed in fibrosing alveolitis may help the understanding of why, in NMRI mice treated with silica particles, lung fibrosis develops in association with a downregulation of TNF-
.
| |
Introduction |
|---|
|
|
|---|
Tumor necrosis factor (TNF)-
is a pivotal mediator in the
pathogenesis of fibrosing alveolitis. TNF-
not only enhances adherence of inflammatory cells to the endothelium, and their migration into alveolar inflammatory sites,
but also activates the production of inflammatory mediators by monocytes and neutrophils (1). In addition, TNF-
induces fibroblast proliferation and collagen messenger
RNA (mRNA) expression, and can inhibit collagen elimination by phagocytic pathways (2). In rat and mouse
models of pulmonary fibrosis induced by silica or bleomycin, treatment with anti-TNF-
antibodies caused a significant reduction of the fibrotic response as indicated by lung
hydroxyproline content (5, 6). Recent studies with transgenic animals have elegantly completed these data: expression of a TNF-
transgene in the murine lung caused spontaneous alveolitis, alveolar disruption, and a progressive fibrotic reaction (7). Using viable motheaten mutant
mice, which naturally develop progressive pulmonary inflammation and fibrosis, Thrall and colleagues (8) have
shown a close association between pulmonary injury and
pulmonary TNF-
levels. In addition, TNF-
/lymphotoxin
(LT)-
double-deficient mice were found resistant to bleomycin-induced fibrosis (9). Several human data have also
shown a clear association between overproduction of
TNF-
and the occurrence of lung fibrosis. Human interstitial lung diseases induced by inhalation of inorganic
dusts such as asbestos and coal mine particles were accompanied by a significant increase in TNF-
release by alveolar macrophages (AM) or blood monocytes (3, 10, 11). In
patients with idiopathic pulmonary fibrosis, high TNF-
levels were also found in bronchoalveolar lavage fluid (BALF) and in supernatants from cultured AM (3, 12).
Besides this wealth of evidence supporting a profibrotic
role for TNF-
, at least two experimental studies have
shown that the lung fibrotic process may in some models
be accompanied by a reduction of TNF-
activity. First,
Ouellet and coworkers (13), using Wistar rats (a strain
considered as relatively resistant to the fibrotic effect of
silica), have shown a reduction in TNF-
production by
bronchoalveolar lavage (BAL) cells from silica-treated rats at all time points considered (up to 28 d after administration). Second, the lung fibrotic response induced by silica in C3H/Hej mice (also considered a relatively resistant
strain) was associated with a reduction of TNF-
production by BAL cells (14). However, both the mechanism and
the possible pathophysiologic significance of such a downregulation of TNF synthesis remain unclear.
We observed a downregulation of TNF-
accompanying the response to silica in NMRI mice. Our study examined the mechanisms involved in this apparently aberrant
response in NMRI mice. The possible relationship of this
downregulation of TNF-
with the lung fibrotic process
was investigated in a comparative mouse model described
previously (15): intratracheal instillation of crystalline silica or manganese dioxide particles was used to produce a
fibrosing or a resolving alveolitis; tungsten carbide (WC)
particles served as innocuous control particles (noninflammatory response).
| |
Materials and Methods |
|---|
|
|
|---|
Animals
Female NMRI mice (Swiss mice that were initially bred at the Naval Medical Research Institute) and Sprague-Dawley rats were purchased from Iffa Credo (Brussels, Belgium). The animals were housed in air-conditioned positive- pressure units (25°C, 50% relative humidity) on a 12-h light/ dark cycle. Interleukin (IL)-10-deficient mice (C57BL/6) (16) were obtained from B&K Universal Limited (Hull, UK). Homozygous mutants were generated by intercrossing of mice heterozygous for IL-10 (17).
Instillation Method
To allow sterilization and inactivation of any trace of endotoxin, particles were heated at 200°C for 4 h before use. Suspensions of WC (d50 = 1 µm; Johnson Matthey, Royston, UK), MnO2 (d50 = 3.7 µm; Sedema, Division of Sadacam SA, Tertre, Belgium), or crystalline silica particles (DQ12; d50 = 2.2 µm; Dr. L. Armbruster, Essen, Germany), or sterile 0.9% saline (controls) were injected directly into the lungs by intratracheal instillation (100 µl/mouse or 400 µl/rat). All instillations were performed on anesthetized animals (sodium pentobarbital, 2 mg/mouse or 6 mg/rat) after surgical opening of the neck.
BAL and Cell Culture
At selected time intervals after treatment, a first group of
animals was killed with sodium pentobarbital (20 mg/
mouse or 60 mg/rat, intraperitoneally) and BAL was performed by cannulating the trachea and infusing the lungs
six times with a volume of 1.5 ml (mouse) or 8 ml (rat) of
sterile saline. The BALF was centrifuged (1,000 × g, 10 min, 4°C ) and the cell-free supernatant of this first lavage
fraction was used for cytokine measurements. BAL was
done with three volumes (1.5 or 8 ml) of sterile saline. The lavage fluids were centrifuged and the cell pellets from all
animals within each treatment group were pooled. Aliquots of the cell suspensions were then used to determine
cell number and viability (trypan blue exclusion method).
Cell differentials were performed on cytocentrifuge preparations fixed in methanol and stained with Diff-Quik
(Dade A. G., Düdingen, Switzerland; 200 cells counted). The alveolar cell suspensions were adjusted to a concentration of 0.5 × 106 viable BAL cells/ml of RPMI 1640 medium (GIBCO BRL, Merelbeke, Belgium) containing lactalbumin hydrolysate (0.1%) and antibiotics (1%). Aliquots
of 1 ml of the cell suspensions were seeded into 24-well
culture plates. BAL cell cultures were stimulated or not with 1 µg/ml of lipopolysaccharide (LPS) (Sigma; Escherichia coli 055:B5) for 3 h. After this period, the culture supernatants were harvested, centrifuged (1,000 × g, 10 min,
4°C), and kept at
80°C until analysis.
Preparation of BAL Cells and Lung Homogenates
In a second group of mice, BAL cells were obtained from
each animal individually through four successive lavages
with sterile saline. After centrifugation, cells obtained
from each mouse were resuspended in 1 ml of cold phosphate-buffered saline (PBS) (GIBCO BRL) and homogenized for 30 s with a Polytron PT1200 homogenizer (Kinematica AG, Lucerne, Switzerland). A third group of mice
was used for measurements of cytokines in the lung; their
whole lungs were excised and placed into Falcon tubes
(Becton Dickinson, Meylan, France) chilled on ice, and 3 ml
of cold PBS was added. The content of each tube was then
homogenized as described earlier. The tubes were centrifuged at 4°C, 2,000 rpm for 10 min, and supernatants were
kept at
80°C until used. The same procedure was used
with rats, except that cells and lungs were homogenized in 3 and 10 ml of PBS, respectively.
Semiquantitative Polymerase Chain Reaction Analysis
RNA from whole lung and BAL cells obtained from saline-
or dust-treated animals (fourth group) were isolated with the
Trizol method (GIBCO BRL). Reverse transcription (RT)
was performed on total RNA (2.5 µg) with an oligodeoxythymidine (oligo[dT]) primer, and amplification was done
for 25-40 cycles by polymerase chain reaction (PCR) with
specific primers as follows: for TNF-
, sense: 5'-GGCCCA GACCCTCACACTCA-3; antisense: 5'-TGGGTGAGGAGCACGTAGTC-3'. For TNFRI (p55), sense: 5'-
CAGGTGGAGATCTCTCCTTG-3'; antisense: 5'-CGAT
CTCGTGCTCGCTCAGC-3'. For TNFRII (p75), sense:
5'-GCAAGCACAGATGCAGT CTG-3'; antisense: 5'-
GGTCAGAGCTGCTACAGACG-3'. For interleukin (IL)-10, sense: 5'-GAGACTTGCTCTTGCACTAC-3';
antisense: 5'-CCTGGAGTCCAGCAGACTCA-3'. For
-actin, sense: 5'-ATGGATGACGATATCGCTGC-3';
antisense: 5'-GCTGGAAGGTGGACAGTGAG-3'.
An aliquot of the PCR reaction was electrophoresed in
a 1% agarose gel and stained with ethidium bromide. Gel
analysis was performed densitometrically through use of
the MCID software system (Imaging Research, St. Catherines, ON, Canada). Results were expressed as arbitrary
units, which were calculated by integration of the intensity
of each pixel over the spot area and normalized for the intensity of the actin signal (cytokine-to-
-actin ratio).
Cytokine and Inflammatory Mediator Measurements
TNF-
and IL-10 levels in the rat model were measured
with commercial enzyme-linked immunosorbent assay
(ELISA) kits (Biosource International, Camarillo, CA;
detection limit: 4 pg/ml and 5 pg/ml, respectively). The
concentrations of mouse TNF-
and IL-10 in BALF and in
BAL cell and lung homogenates were measured with cytokine-specific ELISAs obtained from Biosource International; the detection limits of these ELISAs were 3 pg/ml
and 0.178 pg/ml, respectively. Mouse soluble TNF receptors (sTNF-R) (p75 and p55) were measured with ELISAs
obtained from Genzyme (Cambridge, MA), with detection limits of 12 pg/ml and 15 pg/ml, respectively. Cytokines were expressed per milliliter of recovered lavage
fluid. Levels of TNF-
in culture supernatants were measured both with ELISA (pg/ml) and through bioassay (arbitrary units/ml). TNF-
activity was estimated as described previously (18).
Prostaglandin (PG) E2 was measured with an enzyme
immunoassay (EIA) from Amersham Life Science (Buckinghamshire, England). The biologic activity of transforming growth factor (TGF)-
was estimated with a bioassay
(19), and was expressed as percent of the maximal activity
obtained with a serially diluted TGF-
standard (R&D
Systems, Minneapolis, MN).
In Vitro Neutralization of sTNF-R (p55 and p75)
Neutralization of mouse sTNF-R p55 and p75 was done with soluble antibodies (20) obtained from Genzyme. The mix of antibodies (anti-p55 and anti-p75, 10 µg/ml each) was added to BAL cell cultures 2 h before addition of LPS.
Fluorescence-Activated Cell Sorter Purification of Neutrophils
BAL cells obtained from silica-treated mice (24 h after treatment) were stained with a fluorescein isothiocyanate-conjugated rat monoclonal antimouse Ly-6G (Gr-1) antibody (PharMingen, San Diego, CA) in Hanks' balanced salt solution (GIBCO BRL) and purified by sorting the positive cells (ATC 300; Bruker Spectrospin, Milton, Canada). The purity and viability of purified cells were both > 98%.
Statistics
Treatment-related differences were evaluated through one-way analysis of variance (ANOVA), followed by pairwise comparison with the Student-Newman-Keuls test. Statistical significance was considered at P < 0.05.
| |
Results |
|---|
|
|
|---|
Levels of TNF-
Protein and mRNA in the Fibrotic,
Resolving Inflammatory and Noninflammatory
Models in NMRI Mice
The expression of TNF-
protein and mRNA levels was
examined in three mouse models of pulmonary response
to mineral particles. Levels of TNF-
protein in BALF
from fibrotic, inflammatory, and noninflammatory models
were significantly lower than in controls at 3 d after treatment. Although this downregulation of TNF-
was maintained for up to 120 d in the fibrotic model, TNF-
levels returned to control values after 15 and 30 d in the noninflammatory and resolving inflammatory models, respectively (Figure 1, upper panel).
|
The pattern of TNF-
mRNA expression in the lung
was opposite to that of the protein. In the resolving and fibrotic inflammatory models, mRNA levels were upregulated as compared with those of controls. This effect was
present for up to 30 d in the resolving alveolitis model, and
at all time points examined in the fibrotic model. No effect
on TNF-
mRNA levels was observed in the noninflammatory model (Figure 1, lower panel).
TNF-
Levels in Different Pulmonary Compartments
24 h after Silica Treatment in NMRI Mice
In subsequent experiments, attention was focused on the
early response to silica particles (24 h), in order to investigate the possible determinants of the downregulation of
TNF-
protein observed earlier. Since TNF-
can be produced both extracellularly in BALF and in a membrane-bound form (21), the amounts of TNF-
were assessed in
both lung tissue and in BAL cell homogenates after silica
treatment. Twenty-four hours after silica administration, levels of TNF-
in both lung and BAL cells were significantly decreased as compared with control values, ruling
out a possible redistribution mechanism (in lung: 1,824.9 ± 349.9 pg/ml with saline and 1,152.6 ± 104.7 pg/ml with
silica; P < 0.05; in BAL cells: 353.3 ± 93 pg/ml with saline and 171.4 ± 29.6 pg/ml with silica; P < 0.05). Again
mRNA levels after 24 h did not reflect the TNF-
protein
levels. Following silica administration, TNF-
mRNA expression was increased as compared with that in the control group both in BAL cells and in whole lung (data not
shown). A similar pattern was observed in cultures of
BAL cells incubated with LPS for 3 h. Although the release of TNF-
by BAL cells obtained from animals
treated with silica was significantly reduced both in the
supernatant (saline: 15,906.4 ± 2,435.7 pg/ml; and silica: 4,694.1 ± 2,164.1 pg/ml; P < 0.05) and in adherent cell homogenates (saline: 2,509.8 ± 29.1 pg/ml; and silica: 711.4 ± 55.8 pg/ml; P < 0.05), TNF-
mRNA was upregulated in
BAL cells obtained from silica-exposed animals (data not
shown). These ex vivo results were confirmed in the absence of LPS stimulation and for different durations of
culture, for up to 24 h. Measurements of the biologic activity of TNF-
also showed that supernatants from BAL cell cultures obtained from mice treated with silica contained
significantly lower levels of TNF-
activity than in cultures
from controls (data not shown). This reduction of TNF-
protein and activity was not prevented by the addition of
an antiprotease cocktail (phenylmethylsulfonyl fluoride,
2 mM; leupeptin, 1 µg/ml; pepstatin A, 1 µg/ml; and
1-
antitrypsin, 0.5 mg/ml) to the culture medium (TNF-
biologic activity: saline without antiproteases: 319.6 ± 100.9 U/ml; silica without antiproteases: 56.6 ± 11.6 U/ml; saline
with antiproteases: 408.8 ± 124 U/ml; silica with antiproteases: 58.6 ± 10 U/ml). In addition, the activity of recombinant TNF-
(50, 100, and 500 U/ml) was not degraded
by incubation with BAL cell cultures, culture supernatants, or BALF from silica-treated animals (data not
shown). TNF-
production by cultured BAL cells obtained from the comparative models at different time
points was qualitatively comparable to the in vivo patterns
shown in the upper panel of Figure 1 (data not shown).
To investigate the mechanisms responsible for the
downregulation of TNF-
in NMRI mice, we examined
the production of mediators known to limit the activity or
synthesis of TNF-
. When compared with those of control
cultures, levels of TGF-
were significantly reduced in supernatants from BAL cell cultures obtained 24 h after silica treatment (saline: 51.7 ± 11.1%; and silica: 29.3 ± 3.8% of maximal TGF-
biologic activity; P < 0.05). In
contrast, PGE2 was upregulated after silica treatment in
both BAL cell cultures (saline: 10.5 ± 4.8 pg/ml; and silica:
24.7 ± 5 pg/ml; P < 0.05) and in BALF (saline: < 1 pg/ml;
and silica: 26.7 ± 2.3 pg/ml). However, blocking the production of PGE2 by the addition of indomethacin (1 µg/ml)
did not restore the ex vivo production of TNF-
after silica
treatment (data not shown). Twenty-four hours after instillation, silica treatment stimulated the expression of
mRNAs for the p75 and p55 soluble TNF receptors in
BAL cell homogenates (data not shown). This was accompanied by increased levels of both of these soluble TNF receptor proteins in BALF (p55, saline: 6.9 ± 5.3 pg/ml; and
silica: 121.7 ± 36.1 pg/ml; p75, saline: 59.8 ± 8.0 pg/ml; and
silica: 760.2 ± 0.9 pg/ml; P < 0.05) and in BAL cell homogenates (p55, saline: not detected; and silica: 13.5 ± 6.5 pg/ml; p75, saline: 45.7 ± 1.3 pg/ml; and silica: 71.9 ± 6.1 pg/ml; P < 0.05). Treatment with silica induced a concurrent and pronounced upregulation of IL-10 mRNA expression (data not shown) as well as increased IL-10 protein levels in BAL cell homogenates (saline: 1.3 ± 2 pg/ml;
and silica: 67.0 ± 5.6 pg/ml; P < 0.05).
Levels of sTNF-R and IL-10 in Noninflammatory, Resolving Alveolitis, and Fibrosing Alveolitis Models
To assess the time course of sTNF-R and IL-10 activity
and its relation to the in vivo downregulation of TNF-
protein (Figure 1, upper panel), the levels of both molecules were measured in BALF and BAL cells in the three
comparative models. Lower levels of TNF-
observed in
the resolving and fibrosing alveolitis models were correlated with an overproduction of sTNF-R p55 and p75 in BALF at up to 30 and 120 d in the resolving and fibrotic
alveolitis models, respectively (Figure 2). Similarly, an increased expression of IL-10 mRNA in BAL cells coincided with the reduction of TNF-
. Although IL-10 was
transiently upregulated in the resolving alveolitis model,
persisting upregulation of this cytokine was found in the fibrosing alveolitis model (Figure 3). Measured values for
IL-10 protein in lung homogenates were qualitatively
comparable with the expression patterns observed in BAL
cells (data not shown).
|
|
sTNF-R and IL-10 Regulation of TNF-
Activity
after Silica Administration in NMRI Mice
To assess the functional role of TNF receptor expression in
the downregulation of TNF-
, BAL cells from silica-treated
NMRI mice were first incubated for 2 h with neutralizing
anti-sTNF-R p75 and p55 antibodies or with medium
alone; LPS was then added to the cultures and incubation
was conducted for 3 h. After silica treatment, the levels of
TNF-
in BAL cell supernatants preincubated with antibodies were higher than in cultures from which antibodies were omitted (Figure 4, upper panel). Similarly, in homozygous IL-10-deficient animals (
/
), the inhibition of
LPS-induced TNF-
synthesis ex vivo after silica treatment was found to depend on the ability to produce IL-10
(Figure 4, lower panel).
|
Role of Neutrophils in the Modulation of
TNF-
Production in NMRI Mice
To determine whether a particular type of BAL cell might
contribute to the lower levels of TNF-
observed after silica administration, naive BAL cells isolated from normal
mice (100% of AM) were incubated with BAL cells explanted from silica-treated mice (35% and 65% of AM
and neutrophils [PMN], respectively) or with a fluorescence-activated cell sorter (FACS)-purified population of
PMN (98% of PMN) also obtained from mice treated with
silica particles. Cocultures of naive AM with total BAL
cells or with purified PMN clearly reduced the BAL cells'
LPS-induced production of TNF-
protein (Figure 5). In
addition, BAL cells from mice depleted of PMN by cyclophosphamide pretreatment (200 mg/kg, 3 d before culture)
and instilled with silica produced more TNF-
in culture
than did BAL cells obtained from mice not pretreated with
cyclophosphamide (saline without cyclophosphamide: 100 ± 34.5%; and silica without cyclophosphamide: 29.0 ± 14.7%
of control; and saline with cyclophosphamide = 100 ± 17.8%; and silica with cyclophosphamide = 62.1 ± 17.8%
of control).
|
Comparison of the Response to Silica Particles in Sprague-Dawley Rats and NMRI Mice
Twenty-four hours after instillation of two different doses
of silica particles (2 mg/g and 20 mg/g lung weight), TNF-
responses in BALF and in BAL cell culture supernatants
were compared in rats and in NMRI mice. In NMRI mice,
silica induced a dose-dependent downregulation of TNF-
activity in both BALF and in BAL cell cultures (Figure 6,
upper panel). In contrast, in the rats, ex vivo TNF-
production by BAL cells and TNF-
levels in BALF were significantly increased (Figure 6, lower panel). The AM:PMN
ratio in BALF was typically 30:70 in rats and 35:65 in mice
treated with 20 mg silica, respectively.
|
IL-10 protein levels were compared in BAL cell homogenates 24 h after administration of increasing doses of crystalline silica particles to both rats and mice. Although silica induced a dose-dependent upregulation of IL-10 in mice (Figure 7, upper panel), this cytokine was dose-dependently reduced after administration of equivalent doses of silica in rats (Figure 7, lower panel). IL-10 levels were also reduced in BALF but not in whole-lung homogenates from rats treated with silica (not shown).
|
| |
Discussion |
|---|
|
|
|---|
In NMRI mouse models of lung alveolitis induced by inorganic particles, inflammation and/or fibrosis were accompanied by a downregulation of TNF-
protein. This study
examined the mechanisms involved in the control of this
apparently aberrant TNF-
response, and its possible relationship with the fibrotic process.
What Are the Mechanisms Involved in the
Downregulation of TNF-
in Mice?
At inflammatory sites, although metalloproteinases have
been reported to enhance the release of soluble TNF-
activity (22), an enzymatic degradation of TNF-
, mainly by
elastase, may occur in the vicinity of activated PMN (23).
Because addition of antiproteases did not prevent the reduction of TNF-
release by BAL cells obtained from silica-treated animals in our study, and because the activity of recombinant TNF-
was not abolished when it was incubated
with BAL cell cultures, culture supernatants, or BALFs obtained from silica-treated animals, it appears very unlikely
that a proteolytic activity could be responsible for the observed inactivation of TNF-
in NMRI mice. Furthermore,
the upregulation of other cytokines (IL-6, IL-10, p40 IL-12;
not shown) at the same time points does not support the involvement of proteolytic degradation in the observed downregulation of TNF-
protein in NMRI mice.
TNF-
exerts its biologic activity by interacting with
two distinct TNF receptors, with molecular masses of 55 kD
and 75 kD, respectively (24). Several studies have shown
that after appropriate stimulation, both TNF receptors
may be shed from the cell surface of various cell types, resulting in the expression of soluble forms of these proteins
that retain binding affinities for TNF-
. Although the role
of sTNF-R is still a subject of speculation, soluble forms of
each receptor inhibit TNF-
action in vitro and in vivo,
and can downregulate the inflammatory response (25, 26).
Since addition of a monoclonal anti-TNFR antibody restored to some extent the levels of TNF-
produced by
BAL cell cultures from silica-treated animals, and because
a strong time relationship existed between downregulation
of TNF-
and BALF levels of sTNF-R, it can be concluded that both the 55 kD and 75 kD sTNF-R contributed to the limitation of TNF-
activity observed in the resolving alveolitis and fibrosing alveolitis models. It cannot,
however, be formally excluded that overexpression of cell-associated TNF receptors did not also contribute to the
limitation of TNF-
activity through the binding of TNF-
molecules. Moreover, a mechanism based on the neutralization of TNF-
proteins by specific receptors is consistent with the observed discordance between TNF mRNA
and protein levels. Other investigators have observed that
administration of recombinant sTNF-R to normal or silica-exposed mice markedly decreased the collagen content
in the lung by limiting the activity of TNF-
in collagen
synthesis (27, 28). Therefore, it is plausible that the sTNF-R
overproduction observed in the resolving and fibrosing alveolitis models in our study, as well as in coal workers'
pneumoconiosis (29), represents an attempt of the host to
limit the extension of pulmonary inflammation and fibrosis.
It has also been shown that TNF-
can be negatively
regulated at the posttranscriptional and/or translational
levels by several antiinflammatory mediators, including
PGE2, TGF-
, IL-4, IL-10, and IL-13 (30), which might
also be of particular relevance to understanding the discordance between TNF-
protein and mRNA levels observed in the present study. Since critical roles for PGE2
(36), TGF-
(37), and IL-10 (38) in the lung fibrosis induced by silica have recently been demonstrated, their
overexpression in our mouse model could also have contributed to the observed downregulation of TNF-
. The
possible contribution of TGF-
to the downregulation of
TNF-
was not supported by the finding of reduced production of this cytokine after silica treatment. PGE2 levels
were significantly increased after silica administration, but
addition of the cyclooxygenase inhibitor indomethacin did not restore TNF-
production, suggesting a minor role for
PGE2 in the regulation of TNF-
. Using IL-10-deficient
animals and assessing IL-10 expression in the comparative
models indicated that this cytokine contributed to downregulating TNF-
production. Interestingly, several reports
have shown associations between sTNF-R and IL-10. Because IL-10 has been reported to regulate the cleavage of
TNF receptors from monocytes/macrophages (39) it is possible that, in addition to its effect at the posttranscriptional level, IL-10 could, in the models used in our study, control
TNF-
activity through an increased production of sTNF-R.
The low levels of TNF-
in BALF were associated with
the recruitment of PMN in alveolar spaces (resolving and
fibrosing alveolitis), and the restoration of TNF-
activity
was concurrent with the disappearance of PMN from the
lung (resolving alveolitis after Day 15) (15). When levels
of TNF in BALF measured in all models and at all time
points were pooled, an inverse correlation was found with
the number of recruited PMN (P < 0.0025, r =
0.6998). In addition, neutrophils stimulated in vivo by silica particles suppressed TNF-
release from naive AM. Taken together, these results support a major role of PMN in the
restriction of TNF-
activity, which is in accord with an
earlier report of reduced expression of TNF-
by LPS-stimulated monocytes after addition of activated PMN
(40). Since PMN can produce significant amounts of
sTNF-R and IL-10 both in vitro and in vivo (41, 42), our results are consistent with a downregulation of TNF-
in
the resolving and fibrosing alveolitis models through the
expression of sTNF-R and IL-10 by PMN. In the rat, instillation of silica was also associated with a wide recruitment
of PMN, but in contrast to the mouse, TNF-
activity was
upregulated after treatment with silica (Figure 6). The
cause of this different pattern could conceivably be ascribed to the opposite IL-10 response observed in the rat (Figure 7). Further investigation will be necessary to determine the relevance of this observation.
What Is the Relationship between Downregulated
TNF-
and the Fibrotic Process?
In view of the well-recognized profibrotic activity of TNF-
,
it remains to be explained how fibrosis can develop in association with a downregulation of this cytokine.
Silica administration in different experimental animals
has produced a wide range of pulmonary responses. For
example, it has been shown that rats are highly susceptible
to silica as compared with mice (43, 44). Differences in
susceptibility were also observed in different strains of the
same species. To explain these differences in sensitivity,
investigators have evoked a relation between the capacity
to mount a TNF-
response to silica particles and the degree of fibrotic reaction (14, 45). In species known to be
relatively resistant to the fibrosing effect of silica, a reduction of TNF-
activity may therefore represent an attempt
of the host to reduce the excessive activity of the proinflammatory and profibrotic TNF molecule. In other experimental models, the intensity and/or duration of the inflammatory response induced by an overproduction of
TNF-
is controlled by a secondary overproduction of antiinflammatory cytokines and mediators (46, 47). However, antiinflammatory cytokines involved in this control of TNF activity, including IL-10, which was identified in
the present study, also exert profibrotic effects. We have
previously shown that IL-10 expression reduces the amplitude of the inflammation in response to silica, but also accentuates the fibrotic reaction (38). Other antiinflammatory mediators in the lung, such as TGF-
, IL-11, and IL-13,
were also shown to act as profibrotic cytokines (48).
Therefore, the results obtained in the comparative models
can be interpreted as follows : (1) MnO2 particles induced a transient inflammatory reaction in the lung (resolving alveolitis) that was accompanied by a transient upregulation
of IL-10, contributing to a reduction in TNF-
expression
and in the intensity of the inflammatory response; (2) crystalline silica particles induced a protracted inflammatory
reaction (fibrosing alveolitis) that was accompanied by a
persisting overexpression of IL-10, which also contributed
to limiting lung inflammation and the fibrogenic activity of
TNF-
. However, although this reaction of the host can in
the first instance be regarded as homeostatic, its persistence (up to 120 d in the fibrosing alveolitis model) promoted the development of lung fibrosis. It is also striking
to note that all of these antiinflammatory cytokines described here (IL-10, IL-11, IL-13, TGF-
) are representative of a Th2-polarized immune process, which has been
reported to be associated with fibrosis (51, 52).
In conclusion, the present study shows that in NMRI
mice, the downregulation of TNF-
during the course of
pulmonary inflammation and fibrosis induced by inorganic
particles is associated with and at least partly caused by an
overproduction of sTNF-R and IL-10. This downregulation of TNF-
is interpreted as an attempt of the host to
reduce excessive activity of this proinflammatory and
profibrotic cytokine. Although such a response may confer a certain degree of protection against the development of
fibrosis, by preventing detrimental effects of TNF-
, the
protracted synthesis of profibrotic mediators such as IL-10
can in turn elicit and/or exacerbate the pulmonary fibrotic
process. This mechanism may help in understanding the
apparent contradiction observed in some experimental
models of an association between reduced TNF-
activity and the development of fibrosis.
| |
Footnotes |
|---|
Abbreviations: bronchoalveolar lavage, BAL; BAL fluid, BALF; enzyme-linked immunosorbent assay, ELISA; interlekin, IL; prostaglandin E2,
PGE2; polymorphonuclear neutrophil, PMN; soluble tumor necrosis factor receptor, sTNF-R; transforming growth factor-
, TGF-
; tumor necrosis factor-
, TNF-
.
(Received in original form September 24, 1998 and in revised form January 28, 1999).
Acknowledgments: This work was supported by grant EV5V-CT94-0399 from the Commission of the European Communities (Directorate General XII- Research and Technological Development-Environment, and by the Belgian National Funds for Scientific Research). The authors thank M. Bouyer and A. Thonon for their excellent technical assistance.
| |
References |
|---|
|
|
|---|
1. Tracey, K. J., and A. Cerami. 1994. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annu. Rev. Med. 45: 491-503 [Medline].
2.
Gordon, J. R., and
S. J. Galli.
1994.
Promotion of mouse fibroblast collagen
gene expression by mast cells stimulated via the Fc epsilon RI: role for
mast cell-derived transforming growth factor beta and tumor necrosis factor alpha.
J. Exp. Med.
180:
2027-2037
3. Zhang, Y., T. C. Lee, B. Guillemin, M. C. Yu, and W. N. Rom. 1993. Enhanced IL-1 beta and tumor necrosis factor-alpha release and messenger RNA expression in macrophages from idiopathic pulmonary fibrosis or after asbestos exposure. J. Immunol. 150: 4188-4196 [Abstract].
4. Chou, D. H., W. Lee, and C. A. McCulloch. 1996. TNF-alpha inactivation of collagen receptors: implications for fibroblast function and fibrosis. J. Immunol. 156: 4354-4362 [Abstract].
5. Gossart, S., C. Cambon, C. Orfila, M. H. Seguelas, J. C. Lepert, J. Rami, P. Carre, and B. Pipy. 1996. Reactive oxygen intermediates as regulators of TNF-alpha production in rat lung inflammation induced by silica. J. Immunol. 156: 1540-1548 [Abstract].
6. Piguet, P. F., M. A. Collart, G. E. Grau, A. P. Sappino, and P. Vassalli. 1990. Requirement of tumour necrosis factor for development of silica-induced pulmonary fibrosis. Nature 344: 245-247 [Medline].
7. Miyazaki, Y., K. Araki, C. Vesin, I. Garcia, Y. Kapanci, J. A. Whitsett, P. F. Piguet, and P. Vassalli. 1995. Expression of a tumor necrosis factor-alpha transgene in murine lung causes lymphocytic and fibrosing alveolitis: a mouse model of progressive pulmonary fibrosis. J. Clin. Invest. 96: 250-259 .
8. Thrall, R. S., S. N. Vogel, R. Evans, and L. D. Shultz. 1997. Role of tumor necrosis factor-alpha in the spontaneous development of pulmonary fibrosis in viable motheaten mutant mice. Am. J. Pathol. 151: 1303-1310 [Abstract].
9. Piguet, P. F., S. Kaufman, C. Barazzone, M. Muller, B. Ryffel, and H. P. Eugster. 1997. Resistance of TNF/LT alpha double deficient mice to bleomycin-induced fibrosis. Int. J. Exp. Pathol. 78: 43-48 [Medline].
10. Lassalle, P., P. Gosset, C. Aerts, E. Fournier, J. J. Lafitte, J. M. Degreef, B. Wallaert, A. B. Tonnel, and C. Voisin. 1990. Abnormal secretion of interleukin-1 and tumor necrosis factor alpha by alveolar macrophages in coal workers' pneumoconiosis: comparison between simple pneumoconiosis and progressive massive fibrosis. Exp. Lung Res. 16: 73-80 [Medline].
11. Borm, P. J., N. Palmen, J. J. Engelen, and W. A. Buurman. 1988. Spontaneous and stimulated release of tumor necrosis factor-alpha (TNF) from blood monocytes of miners with coal workers' pneumoconiosis. Am. Rev. Respir. Dis. 138: 1589-1594 [Medline].
12. Bonfield, T. L., J. R. Panuska, M. W. Konstan, K. A. Hilliard, J. B. Hilliard, H. Ghnaim, and M. Berger. 1995. Inflammatory cytokines in cystic fibrosis lungs. Am. J. Respir. Crit. Care Med. 152: 2111-2118 [Abstract].
13. Ouellet, S., H. Yang, R. A. Aubin, R. G. Hawley, G. F. Wenckebach, and I. Lemaire. 1993. Bidirectional modulation of TNF-alpha production by alveolar macrophages in asbestos-induced pulmonary fibrosis. J. Leukoc. Biol. 53: 279-286 [Abstract].
14.
Ohtsuka, Y.,
M. Munakata,
H. Ukita,
T. Takahashi,
A. Satoh,
Y. Homma, and
Y. Kawakami.
1995.
Increased susceptibility to silicosis and TNF-
production in C57BL/6J mice.
Am. J. Respir. Crit. Care Med.
152:
2144-2149
[Abstract].
15.
Lardot, C.,
F. Huaux,
F. Broeckaert,
P. J. Declerk,
M. Delos,
B. Fubini, and
D. Lison.
1998.
Role of urokinase in the fibrogenic response of the lung to
mineral particles.
Am. J. Respir. Crit. Care Med.
157:
617-628
16. Kuhn, R., J. Lohler, D. Rennick, K. Rajewsky, and W. Muller. 1993. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75: 263-274 [Medline].
17. Gazzinelli, R. T., M. Wysocka, S. Hieny, T. Scharton, Kersten, A. Cheever, R. Kuhn, W. Muller, G. Trinchieri, and A. Sher. 1996. In the absence of endogenous IL-10, mice acutely infected with Toxoplasma gondii succumb to a lethal immune response dependent on CD4+ T cells and accompanied by overproduction of IL-12, IFN-gamma and TNF-alpha. J. Immunol. 157: 798-805 [Abstract].
18. Huaux, F., G. Lasfargues, R. Lauwerys, and D. Lison. 1995. Lung toxicity of hard metal particles and production of interleukin-1, tumor necrosis factor-alpha, fibronectin, and cystatin-c by lung phagocytes. Toxicol. Appl. Pharmacol. 132: 53-62 [Medline].
19. Wadhwa M., C. Bird, and A. Tinker. 1991. Quantitative biological assays for individual cytokines. In Cytokines: A Practical Approach, Vol. 23. F. R. Balkwill, editor. IRL Press at Oxford University Press, Oxford, UK. 309-330.
20.
Sheehan, K. C.,
J. K. Pinckard,
C. D. Arthur,
L. P. Dehner,
D. V. Goeddel, and
R. D. Schreiber.
1995.
Monoclonal antibodies specific for murine p55
and p75 tumor necrosis factor receptors: identification of a novel in vivo
role for p75.
J. Exp. Med.
181:
607-617
21. Kriegler, M., C. Perez, K. DeFay, I. Albert, and S. D. Lu. 1988. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell 53: 45-53 [Medline].
22. Black, R. A., C. T. Rauch, C. J. Kozlosky, J. J. Peschon, J. L. Slack, M. F. Wolfson, B. J. Castner, K. L. Stocking, P. Reddy, S. Srinivasan, N. Nelson, N. Boiani, K. A. Schooley, M. Gerhart, R. Davis, J. W. Fitzner, and R. S. Johnson. 1997. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 385: 729-33 [Medline].
23. Nortier, J., P. Vandenabeele, E. Noel, Y. Bosseloir, M. Goldman, and M. Deschodt-Lanckman. 1991. Enzymatic degradation of tumor necrosis factor by activated human neutrophils: role of elastase. Life Sci. 49: 1879-1886 [Medline].
24. Goodwin, R. G., M. R. Alderson, C. A. Smith, R. J. Armitage, T. VandenBos, R. Jerzy, T. W. Tough, M. A. Schoenborn, T. Davis, Smith, and K. Hennen. 1993. Molecular and biological characterization of a ligand for CD27 defines a new family of cytokines with homology to tumor necrosis factor. Cell 73: 447-456 [Medline].
25. Leeuwenberg, J. F., T. M. Jeunhomme, and W. A. Buurman. 1994. Slow release of soluble TNF receptors by monocytes in vitro. J. Immunol. 152: 4036-4043 [Abstract].
26. Pinckard, J. K., K. C. Sheehan, C. D. Arthur, and R. D. Schreiber. 1997. Constitutive shedding of both p55 and p75 murine TNF receptors in vivo. J. Immunol. 158: 3869-3873 [Abstract].
27. Piguet, P. F., and C. Vesin. 1994. Treatment by human recombinant soluble TNF receptor of pulmonary fibrosis induced by bleomycin or silica in mice. Eur. Respir. J. 7: 515-518 [Abstract].
28.
Piguet, P. F.,
F. Tacchini,
Cottier, and
C. Vesin.
1995.
Administration of
anti-TNF-
or anti-CD11a antibodies to normal adult mice decreases lung
and bone collagen content: evidence for an effect on platelet consumption.
Am. J. Respir. Cell Mol. Biol.
12:
227-231
[Abstract].
29. Schins, R. P., and P. J. Borm. 1995. Plasma levels of soluble tumour necrosis factor receptors are increased in coal miners with pneumoconiosis. Eur. Respir. J. 8: 1658-1663 [Abstract].
30. Marchant, A., C. Gueydan, L. Houzet, Z. Amraoui, A. Sels, G. Huez, M. Goldman, and V. Kruys. 1996. Defective translation of tumor necrosis factor mRNA in lipopolysaccharide-tolerant macrophages. J. Inflamm. 46: 114-123 [Medline].
31. Gueydan, C., L. Houzet, A. Marchant, A. Sels, G. Huez, and V. Kruys. 1996. Engagement of tumor necrosis factor mRNA by an endotoxin-inducible cytoplasmic protein. Mol. Med. 2: 479-488 [Medline].
32. Scales, W. E., S. W. Chensue, I. Otterness, and S. L. Kunkel. 1989. Regulation of monokine gene expression: prostaglandin E2 suppresses tumor necrosis factor but not interleukin-1 alpha or beta-mRNA and cell-associated bioactivity. J. Leukoc. Biol. 45: 416-421 [Abstract].
33.
Bogdan, C.,
J. Paik,
Y. Vodovotz, and
C. Nathan.
1992.
Contrasting mechanisms for suppression of macrophage cytokine release by transforming
growth factor-beta and interleukin-10.
J. Biol. Chem.
267:
23301-23308
34.
Mijatovic, T.,
V. Kruys,
D. Caput,
P. Defrance, and
G. Huez.
1997.
Interleukin-4 and -13 inhibit tumor necrosis factor-alpha mRNA translational activation in lipopolysaccharide-induced mouse macrophages.
J. Biol. Chem.
272:
14394-14398
35. Shrikant, P., E. Weber, T. Jilling, and E. N. Benveniste. 1995. Intercellular adhesion molecule-1 gene expression by glial cells: differential mechanisms of inhibition by IL-10 and IL-6. J. Immunol. 155: 1489-1501 [Abstract].
36. Mohr, C., G. S. Davis, C. Graebner, D. R. Hemenway, and D. Gemsa. 1992. Enhanced release of prostaglandin E2 from macrophages of rats with silicosis. Am. J. Respir. Cell Mol. Biol. 6: 390-396 .
37. Williams, A. O., K. C. Flanders, and U. Saffiotti. 1993. Immunohistochemical localization of transforming growth factor-beta 1 in rats with experimental silicosis, alveolar type II hyperplasia, and lung cancer. Am. J. Pathol. 142: 1831-1840 [Abstract].
38.
Huaux, F.,
J. Louahed,
B. Hudspith,
C. Meredith,
M. Delos,
J. Renauld, and
D. Lison.
1998.
Role of interleukin-10 (IL-10) in the lung response to silica
in mice.
Am. J. Respir. Cell Mol. Biol.
18:
51-59
39. Hart, P. H., E. K. Hunt, C. S. Bonder, C. J. Watson, J. J. Finlay, and Jones. 1996. Regulation of surface and soluble TNF receptor expression on human monocytes and synovial fluid macrophages by IL-4 and IL-10. J. Immunol. 157: 3672-3680 [Abstract].
40. Terashima, T., K. Soejima, Y. Waki, H. Nakamura, S. Fujishima, Y. Suzuki, A. Ishizaka, and M. Kanazawa. 1995. Neutrophils activated by granulocyte colony-stimulating factor suppress tumor necrosis factor-alpha release from monocytes stimulated by endotoxin. Am. J. Respir. Cell Mol. Biol. 13: 69-73 [Abstract].
41.
Porteu, F., and
C. Nathan.
1990.
Shedding of tumor necrosis factor receptors by activated human neutrophils.
J. Exp. Med.
172:
599-607
42. Romani, L., A. Mencacci, E. Cenci, R. Spaccapelo, G. Del Sero, I. Nicoletti, G. Trinchieri, F. Bistoni, and P. Puccetti. 1997. Neutrophil production of IL-12 and IL-10 in candidiasis and efficacy of IL-12 therapy in neutropenic mice. J. Immunol. 158: 5349-5356 [Abstract].
43. Oberdorster, G.. 1995. Lung particle overload: implications for occupational exposures to particles. Regul. Toxicol. Pharmacol. 21: 123-135 [Medline].
44. Saffiotti, U., L. N. Daniel, and Y. Mao. 1993. Biological studies on the carcinogenic mechanisms of quartz. In Health Effects of Mineral Dusts. G. D. Guthrie and B. T. Mossman, editors. BookCrafers, Chelsea, MI. 523- 544.
45. Driscoll, K. E., R. C. Lindenschmidt, J. K. Maurer, J. M. Higgins, and G. Ridder. 1990. Pulmonary response to silica or titanium dioxide: inflammatory cells, alveolar macrophage-derived cytokines, and histopathology. Am. J. Respir. Cell Mol. Biol. 2: 381-390 .
46.
de Waal Malefyt, R., J. Abrams, B. Bennett, C. G. Figdor, and J. E. de
Vries.
1991.
Interleukin 10 (IL-10) inhibits cytokine synthesis by human
monocytes: an autoregulatory role of IL-10 produced by monocytes.
J.
Exp. Med.
174:
1209-1220
47.
Gerard, C.,
C. Bruyns,
A. Marchant,
D. Abramowicz,
P. Vandenabeele,
A. Delvaux,
W. Fiers,
M. Goldman, and
T. Velu.
1993.
Interleukin 10 reduces
the release of tumor necrosis factor and prevents lethality in experimental
endotoxemia.
J. Exp. Med.
177:
547-550
48. Jagirdar, J., R. Begin, A. Dufresne, S. Goswami, T. C. Lee, and W. N. Rom. 1996. Transforming growth factor-beta (TGF-beta) in silicosis. Am. J. Respir. Crit. Care Med. 154: 1076-1081 [Abstract].
49. Tang, W., G. P. Geba, T. Zheng, P. Ray, R. J. Homer, C. Kuhn, R. A. Flavell, and J. A. Elias. 1996. Targeted expression of IL-11 in the murine airway causes lymphocytic inflammation, bronchial remodeling, and airways obstruction. J. Clin. Invest. 98: 2845-2853 [Medline].
50.
Hancock, A.,
L. Armstrong,
R. Gama, and
A. Millar.
1998.
Production of
interleukin 13 by alveolar macrophages from normal and fibrotic lung.
Am. J. Respir. Cell Mol. Biol.
18:
60-65
51. Wallace, W. A., E. A. Ramage, D. Lamb, and S. E. Howie. 1995. A type 2 (Th2-like) pattern of immune response predominates in the pulmonary interstitium of patients with cryptogenic fibrosing alveolitis (CFA). Clin. Exp. Immunol. 101: 436-441 [Medline].
52. Furuie, H., H. Yamasaki, M. Suga, and M. Ando. 1997. Altered accessory cell function of alveolar macrophages: a possible mechanism for induction of Th2 secretory profile in idiopathic pulmonary fibrosis. Eur. Respir. J. 10: 787-794 [Abstract].
This article has been cited by other articles:
![]() |
G. Gabriel, K. Klingel, O. Planz, K. Bier, A. Herwig, M. Sauter, and H.-D. Klenk Spread of Infection and Lymphocyte Depletion in Mice Depends on Polymerase of Influenza Virus Am. J. Pathol., September 1, 2009; 175(3): 1178 - 1186. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. G. Haase, A. Klawitter, P. Geyer, and G. B. Baretton Expression of the Immunomodulator IL-10 in Type I Pneumocytes of the Rat: Alterations of IL-10 Expression in Radiation-induced Lung Damage J. Histochem. Cytochem., November 1, 2007; 55(11): 1167 - 1172. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. L. Bonfield, C. M. Swaisgood, B. P. Barna, C. F. Farver, M. S. Kavuru, and M. J. Thomassen Elevated gelatinase activity in pulmonary alveolar proteinosis: role of macrophage-colony stimulating factor J. Leukoc. Biol., January 1, 2006; 79(1): 133 - 139. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Nemery, A. Bast, J. Behr, P.J.A. Borm, S.J. Bourke, Ph. Camus, P. De Vuyst, H.M. Jansen, V.L. Kinnula, D. Lison, et al. Interstitial lung disease induced by exogenous agents: factors governing susceptibility Eur. Respir. J., July 1, 2001; 18(32_suppl): 30S - 42s. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Seiler, B. Rehn, S. Rehn, M. Hermann, and J. Bruch Quartz Exposure of the Rat Lung Leads to a Linear Dose Response in Inflammation but Not in Oxidative DNA Damage and Mutagenicity Am. J. Respir. Cell Mol. Biol., April 1, 2001; 24(4): 492 - 498. [Abstract] [Full Text] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Proc. Am. Thorac. Soc. | Am. J. Respir. Crit. Care Med. |